According to a new report, published by KBV research, The Global Lymphoma Therapeutics Market size is expected to reach $24.9 billion by 2029, rising at a market growth of 7.8% CAGR during the forecast period.
The Target Therapy segment is showcasing a CAGR of 8% during (2023 - 2029). This is due to the increased incidence of Hodgkin and non-Hodgkin lymphoma, increasing the demand for targeted therapies. As a result, targeted therapies have become more prevalent. These therapies offer advantages such as precise targeting of cancer cells due to a significant inventory of products for the treatment of lymphoma, due to which its adoption among patients and healthcare experts to counter lymphoma will increase, surging the segment's expansion in the projected period.
The Non-Hodgkin Lymphoma segment acquired maximum revenue share in the Global Lymphoma Therapeutics Market by Disease Type in 2022 thereby, achieving a market value of $20.9 billion by 2029. This is because it accounts for the majority of lymphoma cases, as non-Hodgkin lymphoma is the most common type of the disease. Both passive and aggressive non-Hodgkin lymphomas are possible. Hence, the growing prevalence of the disease due to various factors will aid the segment's growth.
The Oral Route segment has shown the growth rate of 9.6% during (2023 - 2029). The administration of oral therapy in lymphoma is a dynamic and constantly developing field in business. The frequency of usage varies based on the subtype of the disease. For certain illnesses, like chronic lymphocytic leukemia (CLL), oral treatment has become the preferred therapy method for most patients, effectively replacing intravenous chemotherapy. Clinical trials conducted on patients with CLL have demonstrated that oral treatment plans outperform intravenous chemotherapy in various aspects aiding the segment's growth.
The Hospital Pharmacies segment is generating highest revenue share in the Global Lymphoma Therapeutics Market by Distribution Channel in 2022 thereby, achieving a market value of $10.7 billion by 2029. This is due to the fact that hospital pharmacies play a crucial role in dispensing lymphoma therapeutics to hospitalized patients. Furthermore, the increase in demand for lymphoma therapeutics within medical facilities is the primary factor driving the segment. The drugs are primarily consumed in hospitals and are typically dispensed through hospital pharmacies for patients who are admitted.
The North America market dominated the Global Lymphoma Therapeutics Market by Region in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $9.5 billion by 2029. The Europe market is exhibiting a CAGR of 7.3% during (2023 - 2029). Additionally, The Asia Pacific market would showcase a CAGR of 8.2% during (2023 - 2029).
Full Report: https://www.kbvresearch.com/lymphoma-therapeutics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc. and Eli Lilly And Company.
By Treatment Type
By Disease Type
By Route of Administration
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
